Play­ing a hot hand in can­cer R&D, Pfiz­er scores its 4th drug ap­proval in just 2 months

Pfiz­er’s hot hand in on­col­o­gy con­tin­ued this week with an FDA OK for glas­deg­ib, an oral drug de­signed to throw a mon­key wrench in­to the bi­ol­o­gy dri­ving the hedge­hog path­way in acute myeloid leukemia.

The drug, Pfiz­er’s fourth on­col­o­gy prod­uct ap­proval in just two months, will now be sold as Dau­ris­mo in com­bi­na­tion with chemo for new­ly di­ag­nosed cas­es of AML, when pa­tients can’t tol­er­ate the kind of in­ten­sive chemo regime need­ed to rein in the blood can­cer. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER